PDSB
PDS Biotechnology Corp
NASDAQ · Healthcare · Biotechnology · US
$0.92
−18.89%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.11
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.18
- EPS estimate
- -$0.13
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 2
- Avg surprise (4Q)
- +3.6%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $5.00
- PT range
- $5.00 – $5.00
- Analysts
- 2
2 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.13 | -$0.18 | Miss -38.46% | — |
| May 13, 2026 | -$0.15 | -$0.13 | Beat 13.33% | — |
| Mar 30, 2026 | -$0.20 | -$0.14 | Beat 30.00% | — |
| Nov 13, 2025 | -$0.21 | -$0.19 | Beat 9.52% | — |
| Aug 13, 2025 | -$0.24 | -$0.21 | Beat 12.50% | — |
| May 14, 2025 | -$0.25 | -$0.21 | Beat 16.00% | — |
| Mar 27, 2025 | -$0.29 | -$0.21 | Beat 27.59% | — |
| Nov 14, 2024 | -$0.29 | -$0.29 | In line | — |
| May 15, 2024 | -$0.37 | -$0.30 | Beat 18.92% | — |
| Nov 14, 2023 | -$0.42 | -$0.35 | Beat 16.67% | — |
| Aug 14, 2023 | -$0.37 | -$0.37 | In line | — |
| May 15, 2023 | -$0.31 | -$0.32 | Miss -3.23% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026